The upgrade is based on Moody's expectation of robust earnings growth for Eli Lilly in the coming years. This growth is anticipated to be driven by the company's incretin portfolio, which includes ...
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry ...
Deals, pipeline updates and geopolitical issues drove the conversation at the 2025 JP Morgan Healthcare conference.
Following rumblings of a private equity bidding war late last year, Bain Capital has emer | Bain Capital is laying out 510 ...
Today, we have a look at the White House's reported plans to make major cuts across federal health agencies. Also, Eli Lilly is expanding the ...
Zacks.com on MSN17h
Pharma Stock Roundup: PFE, LLY, NVO, LLY and AZN's Q4 Earnings UpdateThis week was loaded with earnings releases of many large drugmakers. Novo Nordisk NVO, Merck MRK, Pfizer PFE, Eli Lilly LLY, ...
INDIANAPOLIS - Eli Lilly and Company (NYSE: NYSE:LLY), a pharmaceutical giant with a market capitalization of $783.7 billion ...
As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback